Safety and PK of LY3871801 in Healthy Asian and Non-Asian Participants

Phase 1, randomised, double-blind trial of ocadusertib in rheumatoid arthritis (RA) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration up to 24 days. Started Aug 2023; status: completed.